Ceremonial melon

The $34 bln drug maker is the latest to pay over the odds. It’s shelling out a 75 pct premium for Ariad, a biotech with a middling cancer drug. Takeda needs to refill its pipeline as patents on existing treatments expire, but the $5.2 bln purchase price looks too generous.